Successful treatment of two Japanese ESRD cases with severe COVID-19 pneumonia.
Aged
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antiviral Agents
/ therapeutic use
COVID-19
/ complications
Critical Care
Female
Humans
Immunization, Passive
Immunoglobulins, Intravenous
/ therapeutic use
Japan
Kidney Failure, Chronic
/ complications
Male
Renal Dialysis
Respiration, Artificial
SARS-CoV-2
COVID-19 Drug Treatment
COVID-19 Serotherapy
Acute respiratory distress syndrome (ARDS)
Coronavirus disease 2019 (COVID-19)
Diabetic nephropathy
End-stage renal disease (ESRD)
Intravenous immunoglobulin (IVIG)
Tocilizumab
Journal
CEN case reports
ISSN: 2192-4449
Titre abrégé: CEN Case Rep
Pays: Japan
ID NLM: 101636244
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
17
05
2020
accepted:
16
07
2020
pubmed:
28
7
2020
medline:
2
2
2021
entrez:
28
7
2020
Statut:
ppublish
Résumé
Novel coronavirus disease 2019 (COVID-19) is a highly infectious and deadly disease, spreading worldwide. There are limited data about the clinical course of end-stage renal disease (ESRD) patients infected with COVID-19. However, previous cohort studies showed a high mortality rate of ESRD patients infected with COVID-19. We report here two Japanese ESRD patients confirmed with severe COVID-19 pneumonia. Case 1 was a 60-year-old man with ESRD due to diabetic nephropathy who were infected with COVID-19 and exhibited acute respiratory distress syndrome (ARDS) requiring mechanical ventilation and intensive care unit (ICU) admission. He was treated with tocilizumab and intravenous immunoglobulin (IVIG). After 6 days of treatment in ICU, he was extubated. Case 2 was a 68-year-old woman undergoing maintenance hemodialysis for 17 years who also exhibited ARDS due to COVID-19. Her clinical course resembles case 1. Our experience of these two cases indicates that anti-cytokine therapy might be effective for severe COVID-19 pneumonia in ESRD patients.
Identifiants
pubmed: 32715376
doi: 10.1007/s13730-020-00512-7
pii: 10.1007/s13730-020-00512-7
pmc: PMC7382919
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antiviral Agents
0
Immunoglobulins, Intravenous
0
tocilizumab
I031V2H011
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
42-45Références
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.
doi: 10.1056/NEJMoa2002032
Trujillo H, Caravaca-Fontán F, Sevillano Á, et al. SARS-CoV-2 infection in hospitalized patients with kidney disease. Kidney Int Rep. 2020;5(6):905–9.
doi: 10.1016/j.ekir.2020.04.024
Alberici F, Delbarba E, Manenti C, et al. Management of patients on dialysis and with kidney transplant during SARS-COV-2 (COVID-19) pandemic in Brescia, Italy. Kidney Int Rep. 2020;5(5):580–5.
doi: 10.1016/j.ekir.2020.04.001
Toniati P, Piva S, Cattalini M, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020;19(7):102568.
doi: 10.1016/j.autrev.2020.102568
Prete M, Favoino E, Catacchio G, Racanelli V, Perosa F. SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial? Autoimmun Rev. 2020;19(7):102559.
doi: 10.1016/j.autrev.2020.102559